1419518-51-6Relevant articles and documents
INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
-
Paragraph 1804-1805, (2020/03/01)
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
QUINAZOLINE COMPOUND FOR EGFR INHIBITION
-
Paragraph 0210-0211; 0222-0223, (2019/11/21)
Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS
-
Paragraph 000278, (2015/10/05)
ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.